Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGT1A1 Polymorphisms and Irinotecan Toxicity in Advanced Colorectal or Gastric Cancer
NCT01271582Phase 4Unknown
- Sponsor
- Asan Medical Center
- Start
- Jan 2009
- Primary completion
- Jun 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), gastric cancer (GC), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT01271582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271582.